Literature DB >> 24805298

Vasoactive intestinal peptide maintains the nonpathogenic profile of human th17-polarized cells.

Rebeca Jimeno1, Javier Leceta, Carmen Martínez, Irene Gutiérrez-Cañas, Mar Carrión, Selene Pérez-García, Marina Garín, Mario Mellado, Rosa P Gomariz, Yasmina Juarranz.   

Abstract

The cytokine microenvironment modulates CD4 T cell differentiation causing the shift of naïve CD4 T cells into different cell subsets. This process is also regulated by modulators such as vasoactive intestinal peptide (VIP), a neuropeptide with known immunomodulatory properties on CD4 T cells that exert this action through specific receptors, vasoactive intestinal peptide receptor (VPAC)1 and VPAC2. Our results show that the pattern of VIP receptors expression ratio is modified during Th17 differentiation. In this report, we evaluate the capacity of VIP to modulate naïve human cells into Th17 cells in vitro by analyzing their functional phenotype. The presence of VIP maintains the nonpathogenic profile of Th17-polarized cells, increases the proliferation rate, and decreases their Th1 potential. VIP induces the upregulation of the STAT3 gene interaction with the VPAC1 receptor during the onset of Th17 differentiation. Moreover, RAR-related orphan receptor C (RORC), RAR-related orphan receptor A (RORA), and interleukin (IL)-17A genes are upregulated in the presence of VIP through interaction with VPAC1 and VPAC2 receptors. Interestingly, VIP induces the expression of the IL-23R gene through interaction with the VPAC2 receptor during the expansion phase. This is the first report that describes the differentiation of naïve human T cells to Th17-polarized cells in the presence of VIP and demonstrates how this differentiation regulates the expression of the VIP receptors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24805298     DOI: 10.1007/s12031-014-0318-3

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  50 in total

Review 1.  Direct and indirect regulatory mechanisms in TH17 cell differentiation and functions.

Authors:  Y Bi; R Yang
Journal:  Scand J Immunol       Date:  2012-06       Impact factor: 3.487

2.  Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction.

Authors:  Emilie Ceraudo; Régine Hierso; Yossan-Var Tan; Samuel Murail; Christiane Rouyer-Fessard; Pascal Nicole; Jean-Claude Robert; Nadège Jamin; Jean-Michel Neumann; Patrick Robberecht; Marc Laburthe; Alain Couvineau
Journal:  FASEB J       Date:  2012-01-30       Impact factor: 5.191

3.  Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome.

Authors:  B M Lodde; F Mineshiba; J Wang; A P Cotrim; S Afione; P P Tak; B J Baum
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

4.  TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.

Authors:  Mandy J McGeachy; Kristian S Bak-Jensen; Yi Chen; Cristina M Tato; Wendy Blumenschein; Terrill McClanahan; Daniel J Cua
Journal:  Nat Immunol       Date:  2007-11-11       Impact factor: 25.606

Review 5.  Vasoactive intestinal peptide as a healing mediator in Crohn's disease.

Authors:  A Arranz; C Abad; Y Juarranz; J Leceta; C Martinez; R P Gomariz
Journal:  Neuroimmunomodulation       Date:  2008-07-29       Impact factor: 2.492

6.  Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.

Authors:  Yasmina Juarranz; Irene Gutiérrez-Cañas; Begoña Santiago; Mar Carrión; José L Pablos; Rosa P Gomariz
Journal:  Arthritis Rheum       Date:  2008-04

7.  Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis.

Authors:  Irene Gutiérrez-Cañas; Yasmina Juarranz; Begoña Santiago; Carmen Martínez; Rosa P Gomariz; José Luis Pablos; Javier Leceta
Journal:  Brain Behav Immun       Date:  2007-10-24       Impact factor: 7.217

8.  Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells.

Authors:  Eva V Acosta-Rodriguez; Laura Rivino; Jens Geginat; David Jarrossay; Marco Gattorno; Antonio Lanzavecchia; Federica Sallusto; Giorgio Napolitani
Journal:  Nat Immunol       Date:  2007-05-07       Impact factor: 25.606

Review 9.  Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation.

Authors:  Javier Leceta; Rosa P Gomariz; Carmen Martinez; Mar Carrión; Alicia Arranz; Yasmina Juarranz
Journal:  Neuroimmunomodulation       Date:  2007-12-05       Impact factor: 2.492

Review 10.  Regulation and function of innate and adaptive interleukin-17-producing cells.

Authors:  Keiji Hirota; Helena Ahlfors; João H Duarte; Brigitta Stockinger
Journal:  EMBO Rep       Date:  2012-02-01       Impact factor: 8.807

View more
  13 in total

Review 1.  The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.

Authors:  D Ganea; K M Hooper; W Kong
Journal:  Acta Physiol (Oxf)       Date:  2014-12-11       Impact factor: 6.311

2.  The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP.

Authors:  Rebeca Jimeno; Rosa P Gomariz; Marina Garín; Irene Gutiérrez-Cañas; Isidoro González-Álvaro; Mar Carrión; María Galindo; Javier Leceta; Yasmina Juarranz
Journal:  J Mol Med (Berl)       Date:  2014-11-28       Impact factor: 4.599

Review 3.  The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis.

Authors:  Raúl Villanueva-Romero; Irene Gutiérrez-Cañas; Mar Carrión; Selene Pérez-García; Iria V Seoane; Carmen Martínez; Rosa P Gomariz; Yasmina Juarranz
Journal:  J Immunol Res       Date:  2018-08-01       Impact factor: 4.818

4.  Activation of Th lymphocytes alters pattern expression and cellular location of VIP receptors in healthy donors and early arthritis patients.

Authors:  R Villanueva-Romero; I Gutiérrez-Cañas; M Carrión; I González-Álvaro; J M Rodríguez-Frade; M Mellado; C Martínez; R P Gomariz; Y Juarranz
Journal:  Sci Rep       Date:  2019-05-14       Impact factor: 4.379

Review 5.  Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel Disease.

Authors:  Cindy Barnig; Tjitske Bezema; Philip C Calder; Anne Charloux; Nelly Frossard; Johan Garssen; Oliver Haworth; Ksenia Dilevskaya; Francesca Levi-Schaffer; Evelyne Lonsdorfer; Marca Wauben; Aletta D Kraneveld; Anje A Te Velde
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561

Review 6.  An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance.

Authors:  Rosa P Gomariz; Yasmina Juarranz; Mar Carrión; Selene Pérez-García; Raúl Villanueva-Romero; Isidoro González-Álvaro; Irene Gutiérrez-Cañas; Amalia Lamana; Carmen Martínez
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-22       Impact factor: 5.555

Review 7.  The Role of Nociceptive Neurons in the Pathogenesis of Psoriasis.

Authors:  Xuan Zhang; Yanling He
Journal:  Front Immunol       Date:  2020-09-29       Impact factor: 7.561

8.  Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis.

Authors:  Iria V Seoane; Carmen Martínez; Rosario García-Vicuña; Ana M Ortiz; Yasmina Juarranz; Vanessa C Talayero; Isidoro González-Álvaro; Rosa P Gomariz; Amalia Lamana
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

Review 9.  A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases.

Authors:  Carmen Martínez; Yasmina Juarranz; Irene Gutiérrez-Cañas; Mar Carrión; Selene Pérez-García; Raúl Villanueva-Romero; David Castro; Amalia Lamana; Mario Mellado; Isidoro González-Álvaro; Rosa P Gomariz
Journal:  Int J Mol Sci       Date:  2019-12-20       Impact factor: 5.923

10.  VIP Promotes Recruitment of Tregs to the Uterine-Placental Interface During the Peri-Implantation Period to Sustain a Tolerogenic Microenvironment.

Authors:  Lucila Gallino; Vanesa Hauk; Laura Fernández; Elizabeth Soczewski; Soledad Gori; Esteban Grasso; Guillermina Calo; Nora Saraco; Esperanza Berensztein; James A Waschek; Claudia Pérez Leirós; Rosanna Ramhorst
Journal:  Front Immunol       Date:  2020-01-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.